clinical trial · NCT05488405
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Dr. Falk Pharma GmbH·phase2·completed·n = 5
Eosinophilic EsophagitisMesalamine Oral Product
brief summary
Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis
started
Feb 9, 2023
primary completion
Jun 30, 2023
completion
Jul 20, 2023
last updated
Sep 7, 2023
detailed description
This is an open-label, monocentric exploratory phase IIa pilot study, which serves to evaluate the efficacy, safety, and tolerability of treatment with mesalazine oral suspension for the treatment of active eosinophilic esophagitis (EoE).
official title
Open-label, Monocentric Phase IIa Pilot Study Evaluating the Efficacy and Tolerability of a 4-week Treatment With Mesalazine Oral Suspension in Patients With Active Eosinophilic Esophagitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol